Expanded Access To Convalescent Plasma For The Treatment Of Patients With Covid-19

Description

This program provides access to investigational convalescent plasma for hospitalized patients infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Overview

People who recover from COVID-19 do so, at least in part, because their blood contains substances called antibodies, which are capable of fighting the virus that causes the illness. It turns out that for some other diseases caused by viruses, giving people the liquid portion of blood (plasma), obtained from those who have recovered from the virus, leads to more rapid improvement of the disease.

What we're hoping for

We hope that patients with COVID-19 may improve faster if they receive plasma from those who have recovered from
COVID-19, because it may have the ability to fight the virus that causes COVID-19.

UMMS University Campus

About

Support

Resources

The UMass Center for Clinical and Translational Science is part of the
Clinical and Translational Science Award (CTSA) program, funded by the
National Center for Advancing Translational Sciences (Grant #
UL1-TR001453) at the National Institutes of Health (NIH).
NIH Citation Requirements

This is an
official Page of
the University of Massachusetts Medical School